• About us
• Contact

Advertisement

Organisation › Details

ERS Genomics Ltd.

ERS Genomics was formed to commercialise the foundational CRISPR-Cas9 intellectual property held by Dr. Emmanuelle Charpentier. Licenses are available for research and sale of products and services across multiple fields including: research tools, kits, reagents; discovery of novel targets for therapeutic intervention; cell lines for discovery and screening of novel drug candidates; GMP production of healthcare products; production of industrial materials such as enzymes, biofuels and chemicals; and synthetic biology. *

 

	Start	2014-02-17 established
	Industry	CRISPR gene editing technology
	Industry 2	IP services
	Person	Rhodes, Eric (ERS Genomics 201606–202405 CEO before Horizon Discovery + Sigma-Aldrich + Sangamo Biosciences)
	Person 2	Charpentier, Emmanuelle (Helmholtz 201412 Professor at HZI)
	Region	Dublin
	Country	Ireland, Republic of
	Street	88 Harcourt Street
	City	Dublin 2
		Address record changed: 2024-01-05
Basic data	Employees	n. a.
		* Document for »About Section«:
		Record changed: 2024-05-13

Advertisement

More documents for ERS Genomics Ltd.

• [1] ERS Genomics Ltd.. (5/13/24). "Press Release: ERS Genomics Appoints John E Milad as Chief Executive Officer". Stockholm....
• [2] ERS Genomics Ltd.. (3/26/24). "Press Release: Key Charpentier/Doudna CRISPR Patent Upheld by China National Intellectual Property Administration". Dublin....
• [3] ERS Genomics Ltd.. (3/13/24). "Press Release: Ricoh and ERS Genomics Enter into CRISPR/Cas9 License Agreement". Tokyo & Dublin....
• [4] Empyrean Neuroscience, Inc.. (10/18/22). "Press Release: Empyrean Neuroscience Launches with $22M Series A and Genetic Engineering Platform to Advance Pipeline of Neuroactive Compounds Targeting CNS Disorders". New York, NY & Cambridge....
• [5] ERS Genomics Ltd.. (8/17/21). "Press Release: ERS Genomics and Cellular Engineering Technologies Enter CRISPR/Cas9 License Agreement". Dublin & Coralville, IA....
• [6] ERS Genomics Ltd.. (6/1/21). "Press Release: Japanese Patent Office Upholds Key Charpentier/Doudna CRISPR Patent and Allows Third". Dublin....
• [7] ERS Genomics Ltd.. (3/3/21). "Press Release: ERS Genomics Licenses CRISPR Gene Editing Technology to Otsuka Pharmaceutical". Dublin....
• [8] ERS Genomics Ltd.. (3/1/21). "Press Release: ERS Genomics Expands Team With Appointment of Jon Kratochvil as VP Business Development". Dublin....
• [9] ERS Genomics Ltd.. (2/16/21). "Press Release: ERS Genomics and ZeClinics Sign CRISPR/Cas9 License Agreement". Dublin & Barcelona....
• [10] ERS Genomics Ltd.. (12/1/20). "Press Release: Vivlion GmbH Signs Worldwide License Agreement With ERS Genomics for CRISPR/Cas9 Patent Portfolio". Dublin & Frankfurt/M.....

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]

Advertisement

» top

» Imprint  |  » Data Privacy  |  » Contact  |  The use of this website requires to accept the » Disclaimer!   |  A project of [iito] Business Intelligence © 2002-2024. Made in Germany.